Sign In
Buy CHRS
$1.46
-0.0200 (-1.35%)
At Close: Jun 23, 2026
Coherus BioSciences, Inc. (CHRS) Q3 2024 Earnings Call Transcript
11:09pm, Wednesday, 06'th Nov 2024
Coherus BioSciences, Inc. (CHRS) Q3 2024 Earnings Call Transcript
Coherus BioSciences (CHRS) Reports Q3 Loss, Tops Revenue Estimates
06:21pm, Wednesday, 06'th Nov 2024
Coherus BioSciences (CHRS) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.27 per share a year ago.
Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update
04:01pm, Wednesday, 06'th Nov 2024
– Net revenue of $70.8 million in Q3 2024 driven by 30% increase in UDENYCA ® net revenue, quarter-over-quarter –
Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024
04:20pm, Wednesday, 30'th Oct 2024
REDWOOD CITY, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its third quarter 2024 financial results will be released after ma
Coherus BioSciences, Inc. (CHRS) Q2 2024 Earnings Call Transcript
06:08pm, Friday, 09'th Aug 2024
Coherus BioSciences, Inc. (NASDAQ:CHRS ) Q2 2024 Earnings Conference Call August 8, 2024 5:00 PM ET Company Participants Jami Taylor - Head of Investor Relations Dennis Lanfear - President and Chief E
Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates
06:50pm, Thursday, 08'th Aug 2024
Coherus BioSciences (CHRS) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.38 per share a year ago.
Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024
09:00am, Thursday, 01'st Aug 2024
REDWOOD CITY, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its second quarter 2024 financial results will be released after m
Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction
08:26am, Thursday, 27'th Jun 2024
– Transaction aligns with Coherus' strategic focus on oncology – – Transaction aligns with Coherus' strategic focus on oncology –
Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference
09:00am, Thursday, 30'th May 2024
REDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced that senior management will present at the 2024 Jefferies Global Healthcare Con
CHS-114 shown to have an acceptable safety profile with no dose-limiting toxicities (DLTs) in heavily pretreated patients with solid tumors
Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA
09:00am, Thursday, 23'rd May 2024
REDWOOD CITY, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced that senior management will present at the upcoming TD Cowen 5th Annual Oncolog
Coherus BioSciences, Inc. (CHRS) Q1 2024 Earnings Call Transcript
12:07am, Friday, 10'th May 2024
Coherus BioSciences, Inc. (NASDAQ:CHRS ) Q1 2024 Earnings Conference Call May 9, 2024 5:00 PM ET Company Participants Jamie Taylor - Head of Investor Relations Denny Lanfear - Chief Executive Officer
Coherus BioSciences (CHRS) Reports Q1 Loss, Misses Revenue Estimates
06:16pm, Thursday, 09'th May 2024
Coherus BioSciences (CHRS) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.75 per share a year ago.
Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
04:01pm, Thursday, 09'th May 2024
– Net revenue of $77.1 million in Q1 2024 – – CRI and ENB Therapeutics development partnership for toripalimab in ovarian cancer – – New debt and royalty financing replaces $75 million ter
Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan
07:30am, Thursday, 09'th May 2024
– New $38.7 million term loan with a May 2029 maturity – – $37.5 million royalty monetization financing based on future sales of LOQTORZI® and UDENYCA® –
